Antibody targeted thrombin-activatable ?-plasminogen fusion proteins and nanocapsules for the treatment of acute thrombosis

抗体靶向凝血酶激活的β-纤溶酶原融合蛋白和纳米胶囊用于治疗急性血栓形成

• 批准号: nhmrc : 1028145
• 负责人: A/Pr Christoph Hagemeyer
• 金额: $ 35.8万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/antibody-targeted-thrombin-acute-thrombosis/110615
• 关键词: Antibody; targeted; thrombin; activatable; plasminogen

The clinical consequences of atherosclerosis such as myocardial infarction and stroke are the major cause of mortality and morbidity in Australia. Clot dissolving agents have been proven to be beneficial in patients with acute myocardial infarction, vein thrombosis, pulmonary embolism, and stroke. However, the currently available drugs have major limitations in efficacy and in safety. The aim of this project is to develop novel drugs that have the potential to improve both significantly.

动脉粥样硬化的临床后果，如心肌梗死和中风是澳大利亚死亡率和发病率的主要原因。血凝块溶解剂已被证明对急性心肌梗死、静脉血栓形成、肺栓塞和中风患者有益。然而，目前可用的药物在功效和安全性方面具有重大局限性。该项目的目的是开发有潜力显着改善两者的新药。